-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Baird Upgrades Allogene Therapeutics to Outperform, Announces $12 Price Target

Benzinga · 01/06/2023 05:07
Baird analyst Jack Allen upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Outperform and announces $12 price target.